PRINCETON, N.J., May 8 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD)
today announced that it has elected Joseph C. Scodari to its Board of
"We are very pleased to have Joe Scodari join our Board of Directors. He
has enjoyed a distinguished 34-year career as a key leader in the
pharmaceutical and biotechnology industries, and he has a proven track record
of driving growth in large, complex global healthcare businesses," said Joe
Herring, Covance chairman and CEO. "In addition, Mr. Scodari's expertise in
strategy development and pharmaceutical R&D will help us further strengthen
our large client partnerships and enhance our ability to provide productivity
solutions that matter."
"Covance's market leadership and broad service offerings position it well
to help pharmaceutical companies reduce the time and cost of drug
development," Mr. Scodari said. "I look forward to working with Joe and the
esteemed group of board members to take advantage of the significant market
opportunities in the drug development services industry and continue to drive
the company's growth."
Mr. Scodari was recently the worldwide chairman of the Johnson & Johnson
(J&J) Pharmaceuticals Group. In this role, he led efforts to improve research
and development productivity and build a more robust pipeline. He was also a
member of the J&J executive committee and a corporate officer. Before Mr.
Scodari was appointed worldwide chairman of J&J's pharmaceutical business in
2005, he was the company group chairman of J&J's global biopharmaceuticals
business and was responsible for commercial activities in biotechnology and
for specialty businesses in oncology and virology. Under his leadership,
Tibotec Therapeutics launched PREZISTA(R) (darunavir), the company's first
entry into the HIV market. Previously, Mr. Scodari served as company group
chairman for the North America pharmaceuticals business, which included
management responsibility for Ortho-McNeil, Janssen Pharmaceutica, and
Janssen-Ortho Inc., Canada. Prior to these roles, he served as president and
COO, and as a director of Centocor, Inc. and led the organization's
transformation from a focus on research and development to a fully integrated
biopharmaceutical company. Mr. Scodari has also held leadership positions in
Rhone-Poulenc Rorer Pharmaceuticals and Sterling Drug, Inc.
Mr. Scodari recently served as the vice chairman of the board and member
of the executive committee of the Biotechnology Industry Organization (BIO).
He has also served on the Board of Overseers of the Robert Wood Johnson School
of Medicine and on the Board of Trustees of The University of the Sciences in
Philadelphia. He was also previously a member of the Board of Directors of
Pharmacyclics, Inc., a biopharmaceutical company focused on therapies for
cancer. He has a B.A. from Youngstown State University.
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1.5 billion, global operations in more than 20
countries, and more than 8,900 employees worldwide. Information on Covance's
products and services, recent press releases, and SEC filings can be obtained
through its website at http://www.covance.com.
SOURCE Covance Inc.
/CONTACT: Covance Inc., Media: +1-609-419-2060, or Investors:
/Web site: http://www.covance.com/
CO: Covance Inc.
ST: New Jersey
IN: MTC HEA
-- NETH057A --
0000 05/08/2008 16:05 EDT http://www.prnewswire.com